As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Insight Molecular Diagnostics Inc. The largest reported stake is Broadwood Partners, L.P.'s, at 39.7%. 2 filings are on record since February 12, 2026 (Schedule 13D/A, April 27, 2026).
Sell to companies like Insight Molecular Diagnostics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Insight Molecular Diagnostics Inc. has 2 Schedule 13D or 13G filings on record since 2026-02-12. 1 holder's latest filing reports 5% or more of common stock, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Broadwood Partners, L.P. | 39.7% | 12,834,977 | SCHEDULE 13D/A, 2026-04-27 | 2026-04-23 |
Holding shares or following this stake? See who's behind Insight Molecular Diagnostics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Insight Molecular Diagnostics Inc. and the records around it.
Insight Molecular Diagnostics Inc. elsewhere on the record
Companies that share a holder
- Broadwood Partners, L.P. also filed stake reports on 2 other companies: STAAR SURGICAL CO (Mar 2026), Lineage Cell Therapeutics, Inc. (Nov 2025)
Watch Insight Molecular Diagnostics Inc.
Get an email when Insight Molecular Diagnostics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Insight Molecular Diagnostics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Insight Molecular Diagnostics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Insight Molecular Diagnostics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Broadwood Partners, L.P.
The Reporting Persons are filing this Schedule 13D/A to report a change in their respective beneficial ownership percentages. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate. In that regard, the Reporting Persons have been and may continue to be in contact with members of the Issuer's management, board of directors (the "Board of Directors"), other significant shareholders and others regarding alternatives that the Issuer could employ to create significant additional shareholder value over time. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should they determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer. Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-27; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-12 | Broadwood Partners, L.P. | 37.4% | SCHEDULE 13D/A |
| 2026-04-27 | Broadwood Partners, L.P. | 39.7% | SCHEDULE 13D/A |
Questions about who owns Insight Molecular Diagnostics Inc.
Who owns Insight Molecular Diagnostics Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Insight Molecular Diagnostics Inc.: Broadwood Partners, L.P. (39.7%, Schedule 13D/A, filed 2026-04-27).
When did Broadwood Partners, L.P. buy into Insight Molecular Diagnostics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Broadwood Partners, L.P. on this page is the Schedule 13D/A, filed 2026-02-12, reporting 37.4%; its latest, Schedule 13D/A filed 2026-04-27, reports 39.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Insight Molecular Diagnostics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 24, 2025 | Form D, private offering | $21.74M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Insight Molecular Diagnostics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.